Does Cibinqo Cause Infections?
Yes, Cibinqo (abrocitinib), a JAK inhibitor for moderate-to-severe atopic dermatitis, increases the risk of infections. This stems from its mechanism suppressing immune responses, making users more susceptible to bacterial, viral, fungal, and opportunistic infections like herpes zoster or tuberculosis reactivation.[1][2]
Common Infections Reported
Clinical trials and post-marketing data show higher infection rates with Cibinqo than placebo:
- Upper respiratory infections (up to 23% vs. 15% placebo).
- Nasopharyngitis (11-14%).
- Herpes simplex (4-7%).
- Serious infections occurred in 1-3% of patients, including pneumonia and cellulitis.[1][3]
How Does It Increase Infection Risk?
Cibinqo blocks JAK enzymes involved in cytokine signaling for immune cell activation. This dampens inflammation but also impairs pathogen-fighting responses, especially at higher 200 mg doses. Risk rises with concurrent immunosuppressants or in patients with comorbidities like diabetes.[2][4]
Who Faces Higher Risks?
- Elderly patients or those with history of infections.
- Users on corticosteroids or biologics alongside Cibinqo.
- Long-term use: Infections were more frequent after 16 weeks.[1][3]
Black box warnings highlight serious infections, urging screening for latent TB and viral hepatitis before starting.[2]
What Do Patients Experience?
Real-world reports note folliculitis, urinary tract infections, and shingles flares. Some discontinue due to recurrent infections, though many tolerate it with monitoring.[3][5]
How to Manage Risks
Prescribers recommend:
- Baseline infection screening.
- Prompt treatment of any signs (fever, cough).
- Dose reduction or pause during active infections.
- Prophylaxis like antiviral meds for high-risk cases.[2][4]
[1]: Cibinqo Prescribing Information (Pfizer)
[2]: FDA Label for Abrocitinib
[3]: JAAD Study on Abrocitinib Safety
[4]: Drugs.com Side Effects
[5]: DrugPatentWatch.com - Cibinqo Profile